Piper Jaffray Downgrades Obagi Medical Products (OMPI) to Neutral; Significant Upside From Current Estimates Limited
Tweet Send to a Friend
Piper Jaffray & Co. downgrades Obagi Medical Products, Inc. (Nasdaq: OMPI) from Overweight to Neutral. Price target increased from $9 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
